Vividion, a clinical-stage biopharmaceutical company, recently announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion is a wholly owned and independently operating subsidiary of Bayer.

The new facility will significantly increase the company’s chemoproteomics screening capacity. More than half of the expansion will be dedicated to state-of-the-art research labs. It will accommodate strategic growth capabilities and continue to attract and retain top life sciences experts in San Diego, a rapidly growing hub for biotech innovation.

“Vividion has entered an exciting new stage in the company’s development, with multiple programs in clinical trials, a rich discovery portfolio and expansive platform screening efforts focused on bringing more previously undrugged disease-causing targets within the reach of small molecule therapeutics. Our new R&D center and headquarters will provide the infrastructure to execute our strategic vision and continue to lead the way in applying chemoproteomics and covalent chemistry to create first-in-class medicines for patients in need,” said Aleksandra Rizo, Chief Executive Officer of Vividion. 

“Vividion is a key component of Bayer’s innovation strategy and its focus on bringing first-in-class medicines to market to address longstanding unmet medical needs,” said Stefan Oelrich, Member of the Board of Management of Bayer AG and President Pharmaceuticals at Bayer. “This new facility will support our strategic growth opportunities to enable the company to capitalize on the rich array of drug discovery and clinical development opportunities afforded by its pioneering chemoproteomics platform”.

San Diego’s world-renowned biotech cluster is home to hundreds of life science companies and leading research institutes. Such an ecosystem holds great promise for Bayer and Vividion to strengthen its leadership and innovation pipeline. In addition to San Diego, Bayer has successfully developed a local presence in each of the United States’ most innovative life science hubs, including Boston, San Francisco, and Research Triangle Park - North Carolina.